AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17055863 — intervention group
Group type: COMPARATOR
Intervention: Needle knife
Number of subjects: 48
Study 17055863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 12723673 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 0.1 degrees/s
Number of subjects: 69
Study 12723673 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 0.5 degrees/s
Number of subjects: 69
Study 12723673 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive inversion and eversion movements at 2.5 degrees/s
Number of subjects: 69
Study 10680098 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based (HB) exercise program
Number of subjects: 31
Study 10680098 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 31
Study 10680098 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based (CB)
Number of subjects: 31
Study 9056681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 10 mg
Number of subjects: 206
Study 9056681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 20 mg
Number of subjects: 206
Study 9056681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine CC 30 mg
Number of subjects: 206
Study 9056681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 8338988 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble prednisolone + placebo inhalation + terbutaline inhalation
Number of subjects: 123
Study 8338988 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble placebo + budesonide inhalation + terbutaline inhalation
Number of subjects: 123
Study 8338988 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble placebo + placebo inhalation + terbutaline inhalation
Number of subjects: 123
Study 8338988 — intervention group
Group type: COMPARATOR
Intervention: Soluble placebo + placebo inhalation + normal saline inhalation
Number of subjects: 123
Study 2424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg body weight/day for 3 months)
Number of subjects: 90
Study 2424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.75 mg/kg for an additional 3 months)
Number of subjects: 90
Study 2424238 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.1 or 0 mg/kg during the second 3-month period)
Number of subjects: 90
Study 31662976 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified two-lobe technique
Number of subjects: 191
Study 30133840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Formula (Glucerna 1.5 kcal)
Number of subjects: 107
Study 30133840 — intervention group
Group type: COMPARATOR
Intervention: Standard Enteral Formula (Fresubin Energy Fibre)
Number of subjects: 107
Study 27017161 — intervention group
Group type: EXPERIMENTAL
Intervention: EVARREST™ Fibrin Sealant Patch (FP)
Number of subjects: 102
Study 27017161 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 102
Study 24448120 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg/day
Number of subjects: 50
Study 24448120 — intervention group
Group type: COMPARATOR
Intervention: OMP 2.5 mg dexamethasone on 2 consecutive days in a week
Number of subjects: 50
Study 23271912 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated CLA (3 g/day)
Number of subjects: 14
Study 23271912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20359146 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile injections
Number of subjects: 0
Study 17329006 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental fluoride‐based toothpaste containing sodium hexametaphosphate
Number of subjects: 0
Study 17329006 — intervention group
Group type: COMPARATOR
Intervention: Benchmark sodium fluoride paste
Number of subjects: 0
Study 17329006 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 0
Study 12670128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 15
Study 12670128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride
Number of subjects: 15
Study 12670128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 15
Study 12670128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 15
Study 12670128 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 10662743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 40 mg/d)
Number of subjects: 6605
Study 10662743 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6605
Study 9376139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 28
Study 9376139 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 28
Study 8335807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 100
Study 8335807 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.2 million U intravenously over 1 h)
Number of subjects: 100
Study 3552989 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole Vibrio cholerae vaccine alone
Number of subjects: 0
Study 3552989 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole Vibrio cholerae vaccine with B subunit of cholera toxin
Number of subjects: 0
Study 3552989 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 0
Study 3552989 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole vibrio plus B subunit vaccine (preliminary data from field efficacy trial)
Number of subjects: 0
Study 3552989 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole vibrio vaccine alone (preliminary data from field efficacy trial)
Number of subjects: 0
Study 30169575 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention in Spanish (BI-S)
Number of subjects: 310
Study 30169575 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention in English (BI-E)
Number of subjects: 310
Study 27522437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricopharyngeal dilation
Number of subjects: 43
Study 27522437 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical myotomy
Number of subjects: 43
Study 24590546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 25 mg
Number of subjects: 48
Study 24590546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 100 mg
Number of subjects: 48
Study 24590546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate injection 150 mg
Number of subjects: 48
Study 24590546 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 22442277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD, containing 500 IU vitamin D(3) and 150 mg calcium/250 ml)
Number of subjects: 90
Study 22442277 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D(3)-fortified doogh (CDD, containing 500 IU vitamin D(3) and 250 mg calcium/250 ml)
Number of subjects: 90
Study 22442277 — intervention group
Group type: COMPARATOR
Intervention: Plain Persian yogurt drink or doogh (PD, containing 150 mg calcium and no detectable vitamin D(3)/250 ml)
Number of subjects: 90
Study 20457364 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard coaxial phacoemulsification (2.8 mm incisions)
Number of subjects: 135
Study 20457364 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcoaxial phacoemulsification (2.2 mm incisions)
Number of subjects: 135
Study 20457364 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision phacoemulsification (1.2 to 1.4 mm trapezoidal incisions)
Number of subjects: 135
Study 18401017 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 274
Study 15752181 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (one visit)
Number of subjects: 0
Study 15752181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (the other visit)
Number of subjects: 0
Study 12963898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline 300 mg/day orally plus adapalene gel 0.1%
Number of subjects: 242
Study 12963898 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline 300 mg/day orally plus vehicle gel
Number of subjects: 242
Study 10948685 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 895
Study 10948685 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 895
Study 10948685 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 895
Study 10948685 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 895
Study 8640382 — intervention group
Group type: COMPARATOR
Intervention: Heparin-aspirin therapy (Group A)
Number of subjects: 75
Study 8640382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile pneumatic-pump compression of the plantar venous plexus (Group B)
Number of subjects: 75
Study 8640382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both heparin-aspirin and intermittent compression (Group C)
Number of subjects: 75
Study 1354494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin 5,000 IU injected into the abdominal wall
Number of subjects: 101
Study 1354494 — intervention group
Group type: COMPARATOR
Intervention: Sodium heparin 5,000 IU injected into the shoulder
Number of subjects: 101
Study 1354494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (abdominal wall and shoulder)
Number of subjects: 101
Study 6151364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg/kg
Number of subjects: 60
Study 6151364 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 60
Study 6151364 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 60
Study 30617849 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated continuation of PrEP
Number of subjects: 84
Study 30203767 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin eye drops
Number of subjects: 0
Study 30203767 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (control)
Number of subjects: 0
Study 30203767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 0
Study 26986104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin combined with low caloric diet (n=115)
Number of subjects: 166
Study 26986104 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine combined with Metformin (n=51)
Number of subjects: 166
Study 24176681 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (three educational sessions in small interactive groups)
Number of subjects: 163
Study 24176681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 163
Study 22082585 — intervention group
Group type: EXPERIMENTAL
Intervention: Argan oil (15 g/d) for 4 weeks
Number of subjects: 20
Study 22082585 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet, no argan oil)
Number of subjects: 20
Study 19015925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 3818
Study 17429539 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha 1b 10 MU/m2 three times per week (Tiw)
Number of subjects: 120
Study 17429539 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 1b 10MU/m2 three times per week (Tiw) plus lamivudine 3 mg/kg for 6 months
Number of subjects: 120
Study 17429539 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha 1b 10 MU/m2 three times per week (Tiw) plus HBV vaccine 30 microg once a month
Number of subjects: 120
Study 14523887 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg intramuscular ketorolac
Number of subjects: 20
Study 11144694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian model with severity of illness covariates
Number of subjects: 62
Study 11144694 — intervention group
Group type: COMPARATOR
Intervention: General population model without covariates
Number of subjects: 62
Study 8695136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0.75 mg/kg/min for induction and variable-rate propofol infusion up to 0.15 mg/kg/min for maintenance
Number of subjects: 60
Study 8695136 — intervention group
Group type: COMPARATOR
Intervention: Thiopental bolus 2 to 4 mg/kg for induction and isoflurane 0.5% to 1.5% for maintenance
Number of subjects: 60
Study 8695136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 60
Study 8695136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetic groups
Number of subjects: 60
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide treatment
Number of subjects: 10
Study 1628772 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 1628772 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal, nondiabetic subjects)
Number of subjects: 10
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline study in NIDDM patients
Number of subjects: 10
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in NIDDM patients
Number of subjects: 10
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide in NIDDM patients
Number of subjects: 10
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide plus placebo FFAs in NIDDM patients
Number of subjects: 10
Study 1628772 — intervention group
Group type: EXPERIMENTAL
Intervention: FFAs exogenously increased
Number of subjects: 10
Study 6360752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin (Pondocillin) 500 mg twice daily
Number of subjects: 463
Study 6360752 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (Amoxil) 250 mg three times daily
Number of subjects: 463
Study 6360752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin (Pondocillin)
Number of subjects: 463
Study 6360752 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (Amoxil)
Number of subjects: 463
Study 29393671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary proteins in human milk
Number of subjects: 0
Study 29393671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued breastfeeding
Number of subjects: 0
Study 29393671 — intervention group
Group type: COMPARATOR
Intervention: Exclusion diets
Number of subjects: 0
Study 28222465 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Conditioned Plasma (ACP) injection therapy
Number of subjects: 50
Study 28222465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) injection therapy
Number of subjects: 50
Study 26121200 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 + DTaP
Number of subjects: 0
Study 26121200 — intervention group
Group type: COMPARATOR
Intervention: DTaP
Number of subjects: 0
Study 23566212 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac, administered as a small-volume bolus injection every 6 hours for ≥2 days
Number of subjects: 971
Study 23566212 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac
Number of subjects: 971
Study 21752004 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing a kindness questionnaire
Number of subjects: 0
Study 21752004 — intervention group
Group type: COMPARATOR
Intervention: Completing an opinions questionnaire (control)
Number of subjects: 0
Study 21752004 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing an essay about a cherished value
Number of subjects: 0
Study 21752004 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing an essay about kindness
Number of subjects: 0
Study 21752004 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing a questionnaire about kindness
Number of subjects: 0
Study 19803575 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 44
Study 19803575 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 44
Study 16616662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 50
Study 16616662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 50
Study 16616662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive complaints
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging‐associated cognitive decline (AACD)
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild functional impairment
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic MCI
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 40 to 54 years
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 55 to 69 years
Number of subjects: 494
Study 17030753 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 70 to 85 years
Number of subjects: 494
Study 10527954 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (0, 10, 30, or 60 ng/kg/min) combined with inhaled albuterol (200 microg)
Number of subjects: 12
Study 10527954 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (0, 10, 30, or 60 ng/kg/min)
Number of subjects: 12
Study 10527954 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (200 microg)
Number of subjects: 12
Study 10527954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of urodilatin and albuterol
Number of subjects: 12
Study 8892515 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol beer (4.9% alcohol v/v)
Number of subjects: 27
Study 8892515 — intervention group
Group type: COMPARATOR
Intervention: Low alcohol beer (0.9% alcohol v/v)
Number of subjects: 27
Study 1803766 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 0
Study 1803766 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 1803766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6619565 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar exposure with UVA irradiation
Number of subjects: 32
Study 6619565 — intervention group
Group type: COMPARATOR
Intervention: Methods of tar removal (more than water alone)
Number of subjects: 32
Study 31888565 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 160
Study 31888565 — intervention group
Group type: EXPERIMENTAL
Intervention: Running therapy (3 times/week for 16 weeks)
Number of subjects: 160
Study 31888565 — intervention group
Group type: COMPARATOR
Intervention: No treatment (healthy controls)
Number of subjects: 160
Study 30042064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (three doses, intramuscular at 0, 1, and 2 months)
Number of subjects: 63
Study 30042064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three doses, intramuscular at 0, 1, and 2 months)
Number of subjects: 63
Study 30042064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 63
Study 27681760 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 345
Study 27681760 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ALND results with ≥3 positive SLNs
Number of subjects: 345
Study 27681760 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ALND results
Number of subjects: 345
Study 27681760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic stage III
Number of subjects: 345
Study 25343398 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant mandibular overdenture (IOD)
Number of subjects: 255
Study 25343398 — intervention group
Group type: COMPARATOR
Intervention: Standard mandibular complete denture (CD)
Number of subjects: 255
Study 22716205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health literacy intervention consisting of five culturally sensitive workshops over 12 months.
Number of subjects: 0
Study 22716205 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the intervention 12 months after enrollment.
Number of subjects: 0
Study 20002654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 20
Study 20002654 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 20
Study 20002654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IPL and PDL
Number of subjects: 20
Study 18410206 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for parents (4 sessions)
Number of subjects: 90
Study 15838784 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 67
Study 15838784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 67
Study 15838784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Azithromycin + Chloroquine)
Number of subjects: 67
Study 15838784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 12032876 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + 3TC + NVP
Number of subjects: 70
Study 12032876 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T + 3TC + NVP
Number of subjects: 70
Study 12032876 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T + ddI + NVP
Number of subjects: 70
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for hypertrophic obstructive cardiomyopathy
Number of subjects: 0
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for dilated cardiomyopathy
Number of subjects: 0
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for prevention of atrial fibrillation
Number of subjects: 0
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for neurocardiogenic syncope
Number of subjects: 0
Study 10089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing for long QT syndrome
Number of subjects: 0